LONDON, July 18, 2016 /PRNewswire/ -- Regenerative medicine is redefining medical technology synergies by combining stem cell technology with tissue engineering. Advanced biomaterials joint with small molecules and biologics allow to regenerate and restore functions of human tissues and organs. The scope of application has extended far beyond acute injuries, chronic diseases and congenital malformations into therapeutics, research and difficult-to-treat diseases.
New analysis from Frost & Sullivan, Regenerative Medicine - The Future of Therapy (http://www.frost.com/sublib/display-report.do?id=D6EC-01-00-00-00&src=PR), finds that medical device and drug manufacturing companies have been partnering to combine their tissue engineering platforms with the most advanced stem cell therapeutics in order to lower operational costs and time. There have been numerous local, regional and international initiatives to build first-in-class biomanufacturing facilities, while developing expertise in managing progenitor cells, and creating repositories of research and clinical grade stem cells. Some of the countries involved in these initiatives are the United Kingdom, Canada, the United States and Japan.
For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/EU_PR_JSchoneborn_D6EC_13JUL16.
"Companies are steadily streaming into the regenerative medicine space by developing culture medium and reagents before advancing to the cell-based medicines market," said TechVision Industry Analyst Cecilia Van Cauwenberghe. "Their main goal is the development of cell-based medicines using induced pluripotent stem cells (iPSCs). In the long-term, iPSCs will drive the market and advance stem cell therapeutics worldwide."
The booming popularity of regenerative medicine research is attracting substantial funding from both public and private sources. Investments have been particularly high in cell therapies, gene therapies, tissue engineering, biomaterials, and small and biologic molecules in other advanced therapies.
In addition to resolving financial and technology constraints, stakeholders need to address the issues related to process development, manufacturing, logistics and intellectual property protection. Most importantly, the involvement of various countries in regenerative medicine research has stoked a need for new standards and common regulations.
"Domestic and international standardization is crucial for devices, packaging, transportation, equipment, consumable supplies, culture media and reagents and services in the regenerative medicine space," noted Cauwenberghe. "Stakeholders have already started consolidating strategic advisory boards to provide advice on clinical, logistical and regulatory issues, intellectual property strategy, technology transfer and licensing deals."
One of the prominent players in the regenerative medicine is Japan. In 2014, it created the Forum for Innovative Regenerative Medicine (FIRM), comprising 185 firms as well as organizations from the across the world. The health reform in the country in 2015 adapted policies, which encourage collaborations among multiple organizations and contract companies.
Indeed, the regenerative medicine has grown exponentially in recent years despite being nascent in terms of technology readiness for some applications. The escalating synergies among nanotechnology, biotechnology and biomedical engineering will accelerate the introduction of products and technologies that can take regenerative medicine to the next level.
Regenerative Medicine - The Future of Therapy, part of the TechVision (Medical Devices & Imaging and Health & Wellness) subscription, studies the current landscape as well as new trends in regenerative medicine, focusing on technology roadmaps, trends, capabilities and applications targeted. It also covers stakeholder activities, industry initiatives, investment environment and support. Additionally, it offers technology benchmarking for specific applications.
Frost & Sullivan's global TechVision practice is focused on innovation, disruption and convergence and provides a variety of technology based alerts, newsletters and research services as well as growth consulting services. Its premier offering, the TechVision program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate convergence scenarios, possibly disrupt the innovation landscape, and drive transformational growth. View a summary of our TechVision program by clicking on the following link: http://ifrost.frost.com/TechVision_Demo.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Regenerative Medicine - The Future of Therapy
Corporate Communications – Europe
P: +49 (0)69 77033 43
E: [email protected]
SOURCE Frost & Sullivan